184 related articles for article (PubMed ID: 32819341)
1. Development of Caco-2 cells expressing four CYPs via a mammalian artificial chromosome.
Ohta Y; Kazuki K; Abe S; Oshimura M; Kobayashi K; Kazuki Y
BMC Biotechnol; 2020 Aug; 20(1):44. PubMed ID: 32819341
[TBL] [Abstract][Full Text] [Related]
2. Variability in human drug metabolizing cytochrome P450 CYP2C9, CYP2C19 and CYP3A5 activities caused by genetic variations in cytochrome P450 oxidoreductase.
Velazquez MNR; Parween S; Udhane SS; Pandey AV
Biochem Biophys Res Commun; 2019 Jul; 515(1):133-138. PubMed ID: 31128914
[TBL] [Abstract][Full Text] [Related]
3. Establishment of a novel hepatocyte model that expresses four cytochrome P450 genes stably via mammalian-derived artificial chromosome for pharmacokinetics and toxicity studies.
Satoh D; Iwado S; Abe S; Kazuki K; Wakuri S; Oshimura M; Kazuki Y
PLoS One; 2017; 12(10):e0187072. PubMed ID: 29065189
[TBL] [Abstract][Full Text] [Related]
4. Short-term fasting alters cytochrome P450-mediated drug metabolism in humans.
Lammers LA; Achterbergh R; de Vries EM; van Nierop FS; Klümpen HJ; Soeters MR; Boelen A; Romijn JA; Mathôt RA
Drug Metab Dispos; 2015 Jun; 43(6):819-28. PubMed ID: 25795462
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.
Bosilkovska M; Samer C; Déglon J; Thomas A; Walder B; Desmeules J; Daali Y
Basic Clin Pharmacol Toxicol; 2016 Sep; 119(3):284-90. PubMed ID: 27009433
[TBL] [Abstract][Full Text] [Related]
6. CYP450 Genotype/Phenotype Concordance in Mexican Amerindian Indigenous Populations-Where to from Here for Global Precision Medicine?
de Andrés F; Sosa-Macías M; Ramos BPL; Naranjo MG; LLerena A
OMICS; 2017 Sep; 21(9):509-519. PubMed ID: 28873029
[TBL] [Abstract][Full Text] [Related]
7. Development of Caco-2 cells co-expressing CYP3A4 and NADPH-cytochrome P450 reductase using a human artificial chromosome for the prediction of intestinal extraction ratio of CYP3A4 substrates.
Takenaka T; Kazuki K; Harada N; Kuze J; Chiba M; Iwao T; Matsunaga T; Abe S; Oshimura M; Kazuki Y
Drug Metab Pharmacokinet; 2017 Feb; 32(1):61-68. PubMed ID: 28139373
[TBL] [Abstract][Full Text] [Related]
8. Approach to predict the contribution of cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage: the effect of the expression of cytochrome b(5) with recombinant P450 enzymes.
Emoto C; Iwasaki K
Xenobiotica; 2007 Sep; 37(9):986-99. PubMed ID: 17896325
[TBL] [Abstract][Full Text] [Related]
9. MiR-155 and other microRNAs downregulate drug metabolizing cytochromes P450 in inflammation.
Kugler N; Klein K; Zanger UM
Biochem Pharmacol; 2020 Jan; 171():113725. PubMed ID: 31758923
[TBL] [Abstract][Full Text] [Related]
10. Nanostructures of diamond, graphene oxide and graphite inhibit CYP1A2, CYP2D6 and CYP3A4 enzymes and downregulate their genes in liver cells.
Strojny B; Sawosz E; Grodzik M; Jaworski S; Szczepaniak J; Sosnowska M; Wierzbicki M; Kutwin M; Orlińska S; Chwalibog A
Int J Nanomedicine; 2018; 13():8561-8575. PubMed ID: 30587978
[TBL] [Abstract][Full Text] [Related]
11. Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes.
Han SY; Zhao HY; Zhou N; Zhou F; Li PP
J Ethnopharmacol; 2014; 151(1):210-7. PubMed ID: 24157377
[TBL] [Abstract][Full Text] [Related]
12. Combination analysis in genetic polymorphisms of drug-metabolizing enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese population.
Ota T; Kamada Y; Hayashida M; Iwao-Koizumi K; Murata S; Kinoshita K
Int J Med Sci; 2015; 12(1):78-82. PubMed ID: 25552922
[TBL] [Abstract][Full Text] [Related]
13. Significant change of cytochrome P450s activities in patients with hepatocellular carcinoma.
Zhou J; Wen Q; Li SF; Zhang YF; Gao N; Tian X; Fang Y; Gao J; Cui MZ; He XP; Jia LJ; Jin H; Qiao HL
Oncotarget; 2016 Aug; 7(31):50612-50623. PubMed ID: 27203676
[TBL] [Abstract][Full Text] [Related]
14. Influences of cytochrome b5 expression and its genetic variant on the activity of CYP2C9, CYP2C19 and CYP3A4.
Yoo SE; Yi M; Kim WY; Cho SA; Lee SS; Lee SJ; Shin JG
Drug Metab Pharmacokinet; 2019 Jun; 34(3):201-208. PubMed ID: 30992242
[TBL] [Abstract][Full Text] [Related]
15. Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population.
Skadrić I; Stojković O
Int J Legal Med; 2020 Mar; 134(2):433-439. PubMed ID: 31858263
[TBL] [Abstract][Full Text] [Related]
16. Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism.
Galetin A; Houston JB
J Pharmacol Exp Ther; 2006 Sep; 318(3):1220-9. PubMed ID: 16763093
[TBL] [Abstract][Full Text] [Related]
17. Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans.
Thörn HA; Lundahl A; Schrickx JA; Dickinson PA; Lennernäs H
Eur J Pharm Sci; 2011 Jun; 43(3):89-98. PubMed ID: 21447389
[TBL] [Abstract][Full Text] [Related]
18. Development of Robust Quantitative Structure-Activity Relationship Models for CYP2C9, CYP2D6, and CYP3A4 Catalysis and Inhibition.
Gonzalez E; Jain S; Shah P; Torimoto-Katori N; Zakharov A; Nguyễn ÐT; Sakamuru S; Huang R; Xia M; Obach RS; Hop CECA; Simeonov A; Xu X
Drug Metab Dispos; 2021 Sep; 49(9):822-832. PubMed ID: 34183376
[TBL] [Abstract][Full Text] [Related]
19. An improved LC-MS/MS method for simultaneous evaluation of CYP2C9, CYP2C19, CYP2D6 and CYP3A4 activity.
Sreevatsav Adiraju SK; Shekar K; Fraser JF; Smith MT; Ghassabian S
Bioanalysis; 2018 Oct; 10(19):1577-1590. PubMed ID: 30226084
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates.
Derks M; Fowler S; Kuhlmann O
Curr Med Res Opin; 2009 Apr; 25(4):891-902. PubMed ID: 19245299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]